OGEN (Oragenics) Cyclically Adjusted FCF per Share: $-1,017.32 (As of Mar. 2026)


OGEN Oragenics Inc OGEN
30 GF Score
Price $0.61
! 1 Warning Sign
View Full Analysis

What is Oragenics Cyclically Adjusted FCF per Share?

Oragenics OGEN +4.39% 30 Cyclically Adjusted FCF per Share is $-1,017.32 as of Mar. 2026. GuruFocus rates OGEN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Oragenics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.512. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1,017.32 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 19.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.90% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Oragenics was 19.40% per year. The lowest was 3.20% per year. And the median was 6.90% per year.

As of today (2026-07-02), Oragenics's current stock price is $0.6061. Oragenics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-1,017.32. Oragenics's Cyclically Adjusted Price-to-FCF of today is .


Oragenics  (AMEX:OGEN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Oragenics Cyclically Adjusted FCF per Share Related Terms


Oragenics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Oragenics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oragenics Cyclically Adjusted FCF per Share Chart

Oragenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,492.97 -2,116.83 -1,753.36 -1,431.38 -1,108.52

Oragenics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,358.31 -1,304.94 -1,225.12 -1,108.52 -1,017.32

OGEN vs ITRMF, CASIF, AZTR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Oragenics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oragenics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Oragenics's Cyclically Adjusted Price-to-FCF falls into.


OGEN
30GF Score
Oragenics Inc OGEN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oragenics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oragenics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.512/330.2130*330.2130
=-0.512

Current CPI (Mar. 2026) = 330.2130.

Oragenics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -960.000 241.018 -1,315.273
201609 -523.667 241.428 -716.245
201612 -654.667 241.432 -895.406
201703 -633.333 243.801 -857.809
201706 -588.333 244.955 -793.106
201709 -446.667 246.819 -597.585
201712 -453.000 246.524 -606.783
201803 -455.667 249.554 -602.944
201806 -760.333 251.989 -996.360
201809 -350.571 252.439 -458.579
201812 -186.125 251.233 -244.637
201903 -130.059 254.202 -168.949
201906 -134.154 256.143 -172.948
201909 -129.923 256.759 -167.092
201912 -151.423 256.974 -194.579
202003 -147.038 258.115 -188.109
202006 -166.655 257.797 -213.469
202009 -141.394 260.280 -179.384
202012 -95.579 260.474 -121.169
202103 -75.912 264.877 -94.637
202106 -32.469 271.696 -39.462
202109 -70.462 274.310 -84.822
202112 -34.041 278.802 -40.318
202203 -85.433 287.504 -98.124
202206 -52.046 296.311 -58.001
202209 -58.662 296.808 -65.264
202212 -32.919 296.797 -36.625
202303 -28.890 301.836 -31.606
202306 -38.463 305.109 -41.628
202309 -19.025 307.789 -20.411
202312 -12.826 306.746 -13.807
202403 -26.188 312.332 -27.687
202406 -10.232 314.175 -10.754
202409 -9.037 315.301 -9.464
202412 -4.816 315.605 -5.039
202503 -0.116 319.799 -0.120
202506 -1.795 322.561 -1.838
202509 -1.912 324.800 -1.944
202512 -0.664 324.054 -0.677
202603 -0.512 330.213 -0.512

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-1,017.32 mean?
Oragenics (OGEN) has a Cyclically Adjusted FCF per Share of $-1,017.32 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Oragenics and its competitors.
Is Oragenics' Cyclically Adjusted FCF per Share too high?
Oragenics' current Cyclically Adjusted FCF per Share is $-1,017.32. Overall, Oragenics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Oragenics' Cyclically Adjusted FCF per Share compare to ITRMF and CASIF?
Oragenics' Cyclically Adjusted FCF per Share of $-1,017.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Oragenics and its competitors. Oragenics's current Cyclically Adjusted FCF per Share is $-1,017.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oragenics stock overvalued right now?
Oragenics (OGEN) has a current Cyclically Adjusted FCF per Share of $-1,017.32. The current Cyclically Adjusted FCF per Share is $-1,017.32. Oragenics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Oragenics (OGEN), the current Cyclically Adjusted FCF per Share is $-1,017.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oragenics Business Description

Address 9015 Town Center Parkway, Suite 143, Lakewood Ranch, FL, USA, 34202
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
30GF Score

Get the complete analysis for OGEN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price